Healthcare ETF (RYH) Hits New 52-Week High

For investors looking for momentum, Invesco S&P 500 Equal Weight Health Care ETF (RYH) is probably a suitable pick. The fund just hit a 52-week high — up roughly 28.9% from its 52-week low of $ 165.66/share.

Does it have more gains in store? Let’s take a look at the fund and its near-term outlook to gain an insight into where it might be headed:

RYH in Focus

The underlying S&P 500 Equal Weight Health Care Index equally weights stocks in the health care sector of the S&P 500 Index. The fund charges 40 bps in fees (see all HealthCare ETFs here)

Why the Move?

A host of positive news has been driving the healthcare sector higher with the most recent being The Medicines Company’s MDCO innovative approach to cholesterol treatment. Before this, Biogen BIIB spread optimism in the healthcare sector following its Alzheimer’s treatment report. The sector has been hitting headlines this year due to mergers and acquisitions. Valuation is also compelling.

More Gains Ahead?

The fund also has a positive weighted alpha of 16.00, which gives cues of further rally.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free>>

Click to get this free report

Invesco S&P 500 Equal Weight Health Care ETF (RYH): ETF Research Reports

Biogen Inc. (BIIB): Free Stock Analysis Report

The Medicines Company (MDCO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More